Therapeutic effects comparison of Parkinson’s syndrome in the early stage treated by dopamine agonist pramipexole and monoamine oxidase B inhibitor selegiline

Abstract

Objective To compare the clinical efficacy of dopamine agonists pramipexole and monoamine oxidase inhibitors B selegiline in the treatment of early Parkinson’s disease (PD). Methods Ninety patients with earlier stage of PD from May 2012 to October 2015 in People’s Hospital of Xinjiang Uygur Autonomous Region were selected, They were divided into control group (30 cases), pramipexole group (30 cases) and selegiline group (30 cases) according to random number table. The control group were given dopamine (62.5 mg/time of the initial dose, the dose was gradually increased to 125 mg/time according to the treatment effect, 3 times a day), pramipexole group and selegiline group were given pramipexole (1 mg/d) and selegiline (2.5 mg/d) respectively in the basis of dopamine. The unified Parkinson’s disease rating scale (UPDRS) was adopted to evaluate patients, evaluation time respectively before and after treatment 1, 3, 6 months. At the same time, the adverse reactions were observed. Results The total effective rates in the pramipexole group and selegiline group were 93.3% and 90.0%, respectively, which were significantly higher than those in the control group (70.0%, P 0.05). The pramipexole group and selegiline group patients UPDRS score decreased significantly, while the control group of patients UPDRS score decline is not obvious, the difference was statistically significant (P<0.05). For adverse reactions, PD patients pramipexole group of adverse reactions (60%) was higher than selegiline group (6.7%) (P<0.05), but the symptoms can relieve itself. Conclusion The treatment of Pramipexole and selegiline in PD is effective, safe. And, adverse effects were less in the selegiline group. Key words: Parkinson’s symptoms; Pramipexole; Selegiline; Unified Parkinson’s disease rating scale